Intarcia Secures Second Close of the Series EE Equity Financing for an Additional $206M; As Part of the Financing and a New Strategic Initiative, Intarcia Now Aims Its Medici Technology Towards Preventing HIV ? The Bill & Melinda Gates Foundation is committing up...
Dimension Therapeutics Announces FDA Acceptance of Investigational New Drug Application for DTX301 to Treat OTC Deficiency On Track to Initiate Phase 1/2 Global, Multi-Center Clinical Trial by Year End 2016 Most Advanced of Five Inherited Metabolic Disease Programs...
Arvinas Collaborators Present Data on BET PROTAC Degraders at 2016 ASH Annual Meeting NEW HAVEN, Conn., December 6, 2016 – Arvinas LLC, a private biotechnology company creating a new class of drugs known as PROTACs which function via targeted protein degradation,...
Deciphera Pharmaceuticals Reports Encouraging Clinical Results with DCC-2618 in Genetically-defined Cancers with Drug Resistant Mutations Waltham, MA | December 1, 2016 Advanced Kinase Inhibitors with Improved Tumor Targeting Offer Potential for Durable Responses in...
AiCure’s Artificial Intelligence Platform Wins 2016 Scrip Award Using artificial intelligence to optimize patient behavior NEW YORK, Dec. 1, 2016 /PRNewswire/ — AiCure, which uses artificial intelligence (AI) on mobile devices to visually confirm medication ingestion,...
Recent Comments